As Altimmune moves beyond its 2025 fiscal year, the biopharmaceutical firm is squarely focused on a series of pivotal clinical developments scheduled for the near future. Bolstered by a recent successful fundraising effort, the company is gearing up to initiate a critical late-stage trial. The central question for investors is whether its strengthened balance sheet provides sufficient fuel to power through these ambitious clinical objectives.
Pemvidutide: Advancing a Flagship Candidate
The company’s lead therapeutic asset, Pemvidutide, remains the cornerstone of its pipeline. The program gained significant momentum following the late-2025 release of encouraging Phase 2b study data, which demonstrated improvements in key inflammatory and fibrosis markers. This progress was further validated by the U.S. Food and Drug Administration (FDA), which granted Pemvidutide Breakthrough Therapy designation for treating metabolic dysfunction-associated steatohepatitis (MASH).
The clinical roadmap for 2026 is clearly defined. The initiation of a Phase 3 study for MASH is firmly on the calendar. Concurrently, development continues for Pemvidutide as a potential treatment for alcohol use disorder (AUD). Top-line results from the ongoing RECLAIM Phase 2 trial in this indication are anticipated in the third quarter of 2026, making the latter half of the year a crucial period for clinical evaluation.
Should investors sell immediately? Or is it worth buying Altimmune?
A Fortified Financial Position
Despite reporting a net loss of $27.4 million, or $0.27 per share, for the fourth quarter of 2025, Altimmune’s financial health has improved. The company ended 2025 with cash, cash equivalents, and marketable securities totaling $274 million.
This war chest was substantially augmented in January 2026 through a capital raise that generated gross proceeds of $75 million. Consequently, by the end of February, Altimmune’s financial resources stood at approximately $340 million. This capital infusion is viewed as essential for funding the expensive late-stage clinical trials now on the horizon.
Market Performance Amid Sector Headwinds
Despite these operational preparations, Altimmune’s shares have faced recent pressure. Over the past month, the stock declined approximately 30% in value. It closed at €3.02 on Thursday, trading just marginally above its 52-week low of €3.00. Market observers attribute this weakness partly to broader challenges within the healthcare sector, even as the company internally steers toward its next clinical milestones.
Ad
Altimmune Stock: Buy or Sell?! New Altimmune Analysis from March 6 delivers the answer:
The latest Altimmune figures speak for themselves: Urgent action needed for Altimmune investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 6.
Altimmune: Buy or sell? Read more here...
